Media coverage about Immuron (NASDAQ:IMRN) has trended somewhat positive this week, Accern reports. The research firm rates the sentiment of news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Immuron earned a daily sentiment score of 0.08 on Accern’s scale. Accern also assigned media stories about the company an impact score of 47.7034919963702 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

Shares of Immuron (IMRN) opened at 5.4999 on Tuesday. Immuron has a 52-week low of $4.47 and a 52-week high of $16.34. The company has a 50 day moving average of $5.73 and a 200 day moving average of $7.24. The firm’s market capitalization is $14.53 million.

ILLEGAL ACTIVITY WARNING: This report was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another site, it was stolen and republished in violation of US & international copyright and trademark legislation. The correct version of this report can be accessed at https://www.thecerbatgem.com/2017/09/12/somewhat-positive-media-coverage-somewhat-unlikely-to-affect-immuron-imrn-share-price.html.

Immuron Company Profile

Immuron Limited, a microbiome company, focuses on developing and commercializing oral immunotherapeutics for the treatment of various gut medicated diseases in Australia and internationally. The company operates through Research and Development, and HyperImmune Products segments. It has a technology platform that enables a shorter development therapeutic cycle.

Receive News & Stock Ratings for Immuron Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immuron Ltd and related stocks with our FREE daily email newsletter.